Co-granules of xanthan gum and acacia gum

Abstract

The invention relates to a co-granule of xanthan gum and acacia gum having an average diameter of between 50 μm and 1000 μm.

Claims

1. A co-granule consisting of: xanthan gum and acacia gum, wherein the co-granule has a mean diameter of between 100 μm and 300 μm, and a density of between 0.35 mg/ml and 0.7 mg/ml, wherein at most 4 weight % of the particles of the co-granule have a mean diameter of greater than 500 μm and from 65 to 90 weight % of the particles of the co-granule have a mean diameter of greater than 80 μm, wherein the weight ratio between the xanthan gum and the acacia gum varies from 4/1 to 3/1, and wherein said co-granule is prepared by spraying a solution of acacia gum onto solid particles of xanthum gum in a fluidized bed by means of a gas stream, and the co-granules are obtained by drying.

2. The co-granule as claimed in claim 1, wherein the weight ratio between the xanthan gum and the acacia gum is equal to 3/1.

3. A composition comprising at least one tablet wherein said at least one tablet comprise at least one active ingredient and/or at least one nutritional agent, and from 15 to 50 weight % of the co-granules as defined in claim 1.

4. The composition as claimed in claim 3, wherein the at least one tablet further comprises at least one excipient the group consisting of: a diluent, a lubricant, and a cohesion agent.

5. The composition as claimed in claim 4, the at least one tablet comprises, per 100% of its weight, from 20 to 35 weight % of the co-granules, from 0.1 to 60 weight % of an active ingredient and/or of a nutritional agent, from 10 to 50 weight % of the diluent or the cohesion agent, and from 0.5 to 3 weight % of the lubricant.

6. The composition as claimed in claim 3, wherein the composition is a pharmaceutical, food supplement or dietary composition, having a prolonged-release effect.

7. A method for preparing a composition as defined in claim 3, comprising at least one step of forming the at least one tablet by direct compression of a mixture comprising from 15% to 50% by weight of the co-granules and the at least one active ingredient and/or the at least one nutritional agent.

8. The method as claimed in claim 7, wherein the mixture from which the at least one tablet is formed further comprises at least one excipient selected from the group consisting of: a diluent, a lubricant, and a cohesion agent.

9. The method as claimed in claim 7, wherein the composition is a pharmaceutical composition or a food supplement or dietary composition.

10. The co-granule of claim 1, wherein the mean diameter is approximately 150 μm.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows hardness of tablets as a function of compression force.

(2) FIG. 2 show friability of tablets as a function of compression force.

DETAILED DESCRIPTION OF THE INVENTION

(3) In the products which are subjects of the present invention, xanthan gum is used to denote a heteropolymer of monosaccharides and uronic acids, obtained by aerobic fermentation by bacteria of the genus Xanthomonas campestris. Its structure consists of a main chain of β-D-glucose units connected to one another by the 1 and 4 carbons.

(4) There is one branched triholoside every two glucose units in the main chain, in a regular alternating manner; each branch consists of a triholoside composed of two mannoses and a glucuronic acid, of the type: β-d-Manp-(1.fwdarw.4)-β-d-GlcAp-(1.fwdarw.2)-α-d-Manp-(1.fwdarw.3).

(5) Xanthan gums are available in the form of a salt of sodium, potassium or calcium, and are characterized by a molecular weight between 1 000 000 and 50 000 000.

(6) Xanthan gums are represented for example by the products sold under the trade name Rhodicare™ by Rhodia Chimie and under the brand name Keltrol™ CG-T by CP-KELCO.

(7) In the products which are subjects of the present invention, acacia gum is used to denote a complex, branched heteropolymer of monosaccharides and uronic acids, the main chain of which consists of β-D-galactose units connected to one another by the 1 and 3 carbons.

(8) The chains branched to the main chain consist of β-D-galactose units connected to one another by the 1 and 6 carbons, also bearing α-arabinose units, and to a lesser extent β-glucoronosyl units. Both the main chain and the pendent chains contain α-L-arabinosyl, α-L-rhamnopyranosyl, β-D-glucuronopyranosyl and 4-O-methyl-β-D-glucuronopyranosyl units.

(9) Acacia gum is also denoted by the name “gum arabic” and is a solidified exudate of phloem sap, amalgamated naturally or by incision into the trunk and base of trees of the acacia family.

(10) The acacia gum used in the present invention is represented for example by the product sold under the trade name Efficacia™ M by Colloïdes Naturels International.

(11) According to a particular aspect, a subject of the present invention is: a co-granule as defined above, having a mean diameter of between 100 μm and 300 μm, preferably equal to approximately 150 μm. a co-granule as defined above, characterized in that at most 4 weight % of the particles of the co-granule have a mean diameter of greater than 500 μm and from 65 to 90 weight % of the particles of the co-granule have a mean diameter of greater than 80 μm (European Pharmacopeia, 8th Edition 2014 (method 2.9.38)). a co-granule as defined above, having a density of between 0.3 mg/ml and 0.8 mg/ml and preferably of between 0.35 mg/ml and 0.7 mg/ml (European Pharmacopeia, 8th Edition 2014 (method 2.9.34)). a co-granule as defined above, characterized in that the weight ratio between the xanthan gum and the acacia gum varies from 4/1 to 1/1 and is preferably equal to 3/1.

(12) Another subject of the present invention is: a composition comprising at least one tablet containing at least one active ingredient and/or at least one nutritional agent, characterized in that said tablet comprises from 15 to 50 weight % of co-granules, and preferably from 20% to 40%, as defined above. a composition as defined above, characterized in that the tablet also comprises at least one excipient chosen from at least: a diluent, a lubricant, a cohesion agent. a composition as defined above, characterized in that it comprises, per 100% of its weight, from 20 to 35 weight % of co-granules as defined above, from 0.1 to 60 weight % of an active ingredient and/or of a nutritional agent, from 10 to 50 weight % of diluent or cohesion agent, and from 0.5 to 3 weight % of lubricant. a composition as defined above, characterized in that it is a pharmaceutical, food supplement or dietary composition, having a prolonged-release effect.

(13) Another subject of the present invention is: a method for preparing a composition as defined above, comprising at least one step of direct compression of a mixture comprising from 15% to 50% by weight of co-granules as defined above, preferably from 20% to 40%, and at least one active ingredient and/or at least one nutritional agent. a method as defined above, wherein said composition also comprises at least one excipient chosen from at least: a diluent, a lubricant, a cohesion agent.

(14) Another subject of the present invention is:

(15) The use of at least one co-granule as defined above, for the manufacture of a pharmaceutical composition or a food supplement or dietary composition as defined above.

(16) The tablets of the composition which is a subject of the present invention are characterized by: as high a breaking strength as possible (ideally>90 N); as low a friability as possible (ideally<0.5%); a gradual release of the active ingredient after exposure to an aqueous medium (disaggregation time of the tablet>1 h).

(17) The prolonged-release tablets produced with the co-granules comprising xanthan gum and acacia gum have markedly better mechanical properties than the prolonged-release tablets manufactured with only xanthan gum in powder form or only granulated xanthan gum (cf example 2).

(18) The co-granule of the present invention will contain, per 100% of its weight, at least 20 weight % of acacia gum and therefore at most 80 weight % of xanthan gum.

(19) This minimum content of 20 weight % of acacia gum makes it possible to guarantee that the prolonged-release tablets manufactured have a high breaking strength (cf example 1).

(20) The co-granule of the present invention will contain, per 100% of its weight, at least 50 weight % of xanthan gum. This minimum content of 50 weight % of xanthan gum makes it possible to guarantee a gradual release of the active ingredient after exposure to an aqueous medium (cf example 3).

(21) Within the context of the present invention, the term “co-granule” does not mean a simple mixture of at least two compounds, but a combination in which the compounds are intimately connected. In other words, the essential constituents of the co-granules are at least physically connected to one another.

(22) The co-granules of the present invention may be prepared by any of the means available for bringing an acacia gum solution and solid particles of xanthan gum into contact (granulator, fluidized air bed, atomizer, rotary drum, spray-drying towers, etc.).

(23) There are numerous methods described in the literature for preparing co-granules.

(24) Among these known methods, mention may be made of U.S. Pat. No. 3,551,133 describing a method for preparing co-granules of xanthan gum and locust bean gum by spraying an aqueous solution of a mixture of powder of the two gums onto inclined-plate or disk granulators.

(25) GB-2086204 describes a method of the same type.

(26) According to EP-206 368, a solution of gums is sprayed onto a fluidized bed of gums.

(27) The preferred granulation method is, according to the invention, the method according to which a solution of acacia gum is sprayed onto the xanthan gum, in a fluidized bed by means of a gas stream, and the granules are obtained by drying.

(28) However, the prolonged-release tablet may also comprise one or more pharmaceutically and/or nutritionally acceptable excipients, more particularly diluents, cohesion agents, lubricants.

(29) Among the diluents which may be combined in the prolonged-release tablet, mention may be made of lactose, sucrose, mannitol, xylitol, isomalt, calcium hydrogen phosphate, microcrystalline cellulose, starches, and more particularly pregelatinized starches, calcium and magnesium carbonates, etc.

(30) Among the lubricants which may be combined in the prolonged-release tablet, mention may be made of magnesium stearate, talc, sodium stearyl fumarate, hydrogenated vegetable oils, stearic acid, etc.

(31) The present invention may be used for the direct compression of nutritional agents and active ingredients belonging to all classes of medications intended for oral administration.

(32) Among the active ingredients used in compositions according to the present invention, mention may be made of nonsteroidal anti-inflammatories and antirheumatics (ketoprofen, ibuprofen, flurbiprofen, indomethacin, phenylbutazone, allopurinol, etc.), analgesics (paracetamol, phenacetin, aspirin, etc.), antitussives (codeine, codethyline, alimemazine, etc.), sterols (hydrocortisone, cortisone, progesterone, testosterone, triamcinolone, dexamethazone, betamethazone, paramethazone, fluocinolone, beclomethazone, etc.), barbiturates (barbital, allobarbital, phenobarbital, pentobarbital, amobarbital, etc.), antimicrobials (pefloxacin, sparfloxacin, and derivatives of the class of quinolones, tetracyclines, synergistins, metronidazole, etc.), medications intended for treating allergies, antiasthmatics, vitamins (vitamin A, vitamin E, vitamins of the D group, vitamin K), antispasmodics and antisecretory agents (omeprazole), cardiovascular agents and cerebral vasodilators (quinacainol, oxprenolol, propanolol, nicergotine, etc.), cerebroprotective agents, hepatic protective agents, therapeutic agents for the gastrointestinal tract, vaccines, antihypertensives and cardioprotective agents, such as beta blockers and nitro derivatives. Among the nutritional agents used in compositions according to the present invention, mention may be made of mineral salts (calcium, magnesium, iron, zinc, sodium, potassium, copper, manganese, etc.), plant extracts (burdock, borage, lemon balm, hops, lavender, white deadnettle, cherry stalk, meadowsweet, ginseng, guarana, ginger, passion flower, valerian, hawthorn, lime, verbena, etc.) and fatty acids (omega 3, omega 6).

(33) According to the invention, the compression operation following mixing of the excipients and the active ingredient or nutritional agent is generally carried out under a force which may range from 6 to 20 kN (measured at the compression roller) and preferably of the order of 8 to 12 kN.

(34) This compression operation is preferably preceded by a pre-compression under a force which may range from 0.5 to 2.5 kN.

(35) High compression rates may be achieved by virtue of the method according to the invention, without however adversely affecting the quality of the tablets. It is especially possible to achieve rates of greater than 150 000 tablets per hour, without causing any splitting.

(36) It is understood that the tablets obtained according to the invention may optionally be film-coated according to customary methods. The film-coating operation is facilitated by the fact that no splitting occurs during the operation.

(37) In the following text or the above text, unless indicated otherwise, the percentages and parts are by weight.

(38) The following examples illustrate the present invention without, however, limiting it.

PROCEDURE FOR PREPARING TABLETS

(39) 700 g of the powder mixture consisting of an active ingredient, in this case synthetic caffeine, and the various matrix constituents, namely the xanthan gum-acacia gum co-granule, and optionally the other excipients, such as for example dicalcium phosphate, are mixed beforehand in a Turbula T2c type mixer. The powder mixture also contains the lubricant, name magnesium stearate metered in at 1% by weight to said mixture.

(40) The compression is carried out under a force of 8.5 kN (measured at the compression roller) using a rotary machine of Picola Nova type, which makes it possible to produce, from the powder mixture, 1000 tablets, each of 500 mg.

EXAMPLES

Example 1

(41) Co-granules containing different proportions by weight of xanthan gum and acacia gum were manufactured.

(42) Prolonged-release tablets were prepared with these co-granules according to the following composition:

(43) TABLE-US-00001 Mixture composition: Formula (%): Co-granules 35% Synthetic caffeine 20% CMC (carboxymethyl cellulose) 33% Vivapur (JRS) Calcium Hydrogen Phosphate dihydrate Ph 11% Eur Emcompress (JRS) Mg stearate  1%

(44) The breaking strength of the tablets was controlled according to the methods of the European Pharmacopeia, 8th Edition 2014 (method 2.9.8).

(45) TABLE-US-00002 Co-granule composition by weight: % xanthan 100% 90% 80 75 % acacia  0% 10% 20 25 Breaking strength of the 72 78 91 103 tablets (N)

(46) At least 20% acacia gum in the co-granule makes it possible to obtain tablets with a breaking strength of greater than 90 N.

Example 2

(47) Prolonged-release tablets with 2 types of commercially available gum were formulated: Xanthan gum powder (mean particle diameter: 74 μm) Granulated xanthan gum (mean particle diameter: 185 μm)

(48) In parallel, prolonged-release tablets were manufactured with the co-granules of xanthan gum and acacia gum (75/25 w/w) of mean diameter: 150 μm.

(49) The same compression formula was used:

(50) TABLE-US-00003 Mixture composition: Formula (%): Xanthan-acacia co-granules, or 35% xanthan gum powder, or granulated xanthan gum Synthetic caffeine 20% CMC 33% Vivapur (JRS) Calcium Hydrogen Phosphate dihydrate Ph Eur. 11% Emcompress (JRS) Mg stearate  1%

(51) The mixtures were compressed on the Picola Noca rotary press with the following parameters: 8 punches 11 mm in diameter targeted weight: 500 mg/tablet

(52) Various compression forces were tested.

(53) The breaking strength of the tablets and their friability were controlled according to the methods of the European Pharmacopeia, 8th Edition 2014 (methods 2.9.7 and 2.9.8).

(54) The following results were obtained with the xanthan gum powder:

(55) TABLE-US-00004 Compression Breaking strength % friability of the force (kN) of the tablets (N) tablets 11 43 1.4 13 57 1.2 18 73 0.7 23 82 0.6 25 87 0.6 27 92 0.6

(56) Results with granulated xanthan gum:

(57) TABLE-US-00005 Compression force Breaking strength % friability of the (kN) of the tablets (N) tablets 9 54 1.1 13 63 1.0 15 75 0.8 20 80 0.8 23 88 0.7 26 92 0.8 29 92 0.8

(58) Results with xanthan/acacia (75/25) co-granule:

(59) TABLE-US-00006 Compression force Breaking strength % friability of the (kN) of the tablets (N) tablets 11 103 0.6 14 116 0.4 22 142 0.4 29 162 0.4

(60) FIGS. 1 (hardness of the tablets as a function of the compression force) and 2 (friability of the tablets as a function of the compression force) illustrate that at equal compression force, the tablets manufactured with the xanthan/acacia co-granule have better mechanical properties than the tablets with xanthan gum: a higher breaking strength and a lower friability.

(61) This applies irrespective of the particle size of the control xanthan gum (powder or granulated).

Example 3

(62) Co-granules containing different proportions by weight of xanthan gum and acacia gum were manufactured. Tablets were prepared with these co-granules according to the following composition:

(63) TABLE-US-00007 Mixture composition: Formula (%): Co-granules 35% Synthetic caffeine 20% CMC 33% Vivapur (JRS) Calcium Hydrogen Phosphate dihydrate 11% Ph Eur. Emcompress (JRS) Mg stearate  1%

(64) The disaggregation time of the tablets was controlled according to the methods of the European Pharmacopeia, 8th Edition 2014 (method 2.9.1).

(65) TABLE-US-00008 Co-granule composition by weight % xanthan 100% 75 50 % acacia  0% 25 50 Disaggregation time >7 hours 6.5 hours 90 minutes of the tablets (N)

(66) At least 50% xanthan gum in the co-granule makes it possible to obtain prolonged-release tablets.